Expert Suggests Changes in Fungus Treatment

BY LAIRD HARRISON

EXPERT ANALYSIS FROM A PEDIATRIC UPDATE

LAS VEGAS – Competition among large retailers is bringing down the cost of terbinafine, but griseofulvin is still better for many fungal infections, according to Dr. Lawrence F. Eichenfield.

The ideal prescription depends on the type of fungus and the site of the infection, said Dr. Eichenfield, chief of pediatric and adolescent dermatology at the University of California, San Diego, at the pediatric update sponsored by the American Academy of Pediatrics California Chapter 9. Topical medications alone can seldom cure tinea capitis because the fungus finds protection inside hair follicles, but he advised using them in combination with systemic drugs.

The signs of tinea capitis include scaling, pustules, kerion, black dots, alopecia, adenopathy, and autoeczematization (also



Topical medications alone seldom cure tinea capitis, but they can be used in combination with systemic drugs.

DR. EICHENFIELD

known as id reaction). The condition can resemble seborrheic dermatitis, psoriasis, folliculitis, and other diseases. "So it's worth doing a routine culture," said Dr. Eichenfield, adding that it's fairly easy to obtain a specimen with a toothbrush, cotton swabs, or bacterial culturettes.

The most common culprit is *Trichophyton tonsurans*, which is spread by human contact. The second most common cause is *Microsporum canis*, which is spread by cats.

Family coinfection can contribute to treatment failure, so inquire about tinea capitis and tinea corporis in other affected family members and pets, said Dr. Eichenfield. The standard therapy for tinea capitis is microsized griseofulvin (20 mg/kg) for 6-8 weeks, he advised.

The only other approved drug is terbinafine granules, and these are hard to obtain, he said, but itraconazole and fluconazole might also work.

Particularly if griseofulvin fails, Dr. Eichenfield recommended terbinafine 4-8 mg/kg per day for 4 weeks. But one recent study found that griseofulvin was much better than terbinafine for *M. canis* (J. Am. Acad. Dermatol. 2008;59:41-54).

The same organisms, along with *T. rubrum* and *T. mentagrophytes*, can cause tinea corporis. Patients present with red scaling plaque, often with an active border. Central clearing may give the lesions a ring shape.

They can be treated with a wide variety of topical drugs, among them clotrimazole, econazole, oxiconazole, ciclopirox, terbinafine, and ketoconazole. Systemic treatment should be reserved for extensive disease or special circum-

stances, such as for wrestlers. The best systemic treatment is griseofulvin, 15-20 mg/kg (5-10 mg/kg ultramicrosize), said Dr. Eichenfield.

Although fewer than 1% of children suffer from onychomycosis, the proportion increases with age; more than a third of adults older than 70 years have the disease. In children who are not severely affected, the disease can go untreated.

There is no approved treatment for onychomycosis in children, but Dr. Eichenfield said that he is comfortable recommending terbinafine as long as parents are informed that this is an offlabel use of the drug. "Terbinafine is so cost effective," he said. "You can get it for \$4-\$7 per month. It used to be \$1,200 for a full course."

His recommended dosages to treat onychomycosis are the following:

- ► For children weighing less than 20 kg: 62.5 mg/day.
- ► For children weighing 20-40 kg: 125 mg/day
- ► For children weighing more than 40 kg: 250 mg/day.

"It's recommended that you get baseline lab work," he said. "Many of us will repeat [it] 1 month into the therapy."

Dr. Eichenfield reported having no relevant conflicts of interest.

For patients with type 2 diabetes whose blood glucose is not well controlled with orals alone

ADVERTISEMENT

IS IT TIME TO RETHINK INSULIN?

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day. Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Please see additional Important Safety Information for Lantus® continued on the next page.

From the maker of LANTUS® SoloSTAR®

